Sign In
Buy TSHA
$5.86
-0.0150 (-0.255%)
At Close: Jul 31, 2026
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript
02:36pm, Tuesday, 04'th Nov 2025
Taysha Gene Therapies, Inc. ( TSHA ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations Sean Nolan - C
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 04'th Nov 2025
TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which wa
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
08:00am, Tuesday, 28'th Oct 2025
DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.1% – Time to Buy?
03:00am, Wednesday, 22'nd Oct 2025
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report)'s stock price was up 9.1% during mid-day trading on Tuesday. The stock traded as high as $5.33 and last traded at $5.15. Approximately 5,55
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Moderate Buy” by Analysts
01:48am, Wednesday, 22'nd Oct 2025
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, MarketBeat
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
04:01pm, Thursday, 16'th Oct 2025
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic fle
Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential
10:07am, Monday, 06'th Oct 2025
Taysha Gene Therapies, Inc.'s lead asset is TSHA-102. This is an intrathecal AAV9 gene therapy for Rett with a 100% Phase 1/2 responder rate and favorable safety. The FDA granted it a Breakthrough The
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 03'rd Oct 2025
DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b
Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Sep 2025
DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
04:01pm, Tuesday, 12'th Aug 2025
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.09 per share a year ago.
Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript
01:38pm, Tuesday, 12'th Aug 2025
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08:01am, Tuesday, 12'th Aug 2025
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from t
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
04:05pm, Tuesday, 05'th Aug 2025
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-
